Goji berries and eye pigment: a pilot marker, not proven vision protection
A small 90-day trial measured macular pigment rather than the prevention of eye disease.

Illustrative food image, not a photograph of the study intervention.
A small comparison in healthy adults
The goji berry trial enrolled 27 healthy adults aged 45–65 years in a randomized, unmasked, parallel-arm study. Participants consumed either 28 g of goji berries or a supplement providing 6 mg lutein and 4 mg zeaxanthin, five times weekly for 90 days. The study measured macular pigment optical density, abbreviated MPOD, and skin carotenoids. That setup makes this a pilot comparison of two interventions, not a study comparing berries with an otherwise identical diet without berries. The small sample, lack of masking, and short observation period should remain visible whenever the findings are summarized for a general audience.
Li X, Holt RR, Keen CL, Morse LS et al.. Nutrients, 2021. PMID 34959963 · DOI
Where pigment measurements changed
After 90 days, MPOD increased significantly in the goji berry group at retinal eccentricities of 0.25 and 1.75, with P values of 0.029 and 0.044, respectively. No changes were noted in the lutein-zeaxanthin supplement group. Those are the specific findings reported in the abstract; they should not become a claim that every retinal measurement improved. Nor does one arm showing a significant change while the other does not, by itself, establish a statistically significant difference between the arms. The abstract does not provide a between-group effect estimate that would justify declaring goji berries conclusively superior to the supplement.
Li X, Holt RR, Keen CL, Morse LS et al.. Nutrients, 2021. PMID 34959963 · DOI
Skin carotenoids were another marker
The investigators also found significant increases in skin carotenoids in the goji berry group at day 45 and day 90, with P values of 0.025 and 0.006. They did not report corresponding changes in the supplement group. This adds a second measured response, but it remains a marker rather than a clinical eye-disease outcome. In the paper's framing, MPOD is a biomarker relevant to age-related macular degeneration. The reported results do not give numbers of people who avoided that disease or retained better vision. Separating pigment and carotenoid measurements from clinical outcomes keeps the pilot's contribution clear without diminishing its rationale.
Li X, Holt RR, Keen CL, Morse LS et al.. Nutrients, 2021. PMID 34959963 · DOI
A promising question, not a menu mandate
The authors suggest that regular goji berry intake may help prevent or delay age-related macular degeneration, but the abstract's evidence consists of pigment and carotenoid changes over 90 days in healthy middle-aged adults. Disease prevention therefore remains a possibility rather than an outcome established by this trial. The study amount and schedule describe what participants consumed; they are not a personal dosing instruction. An oats recipe can accompany the topic as a culinary base, without claiming that the recipe reproduces the intervention. The authors declared no conflict of interest, while the small, unmasked pilot design still limits how firmly to interpret the findings.
Li X, Holt RR, Keen CL, Morse LS et al.. Nutrients, 2021. PMID 34959963 · DOI